---
document_datetime: 2023-09-21 18:39:21
document_pages: 26
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/tadalafil-generics-epar-public-assessment-report_en.pdf
document_name: tadalafil-generics-epar-public-assessment-report_en.pdf
version: success
processing_time: 8.3991233
conversion_datetime: 2025-12-27 21:57:37.669236
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

10 November 2016 EMA/803097/2016 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Tadalafil Generics

International non-proprietary name: tadalafil

Procedure No. EMEA/H/C/004297/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................9                                 |                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................9      |                                                                                                      |
| 1.2. Steps taken for the assessment of the product.......................................................10                |                                                                                                      |
| 2. Scientific discussion                                                                                                   | ..............................................................................11                     |
| 2.1. Introduction.......................................................................................................11 |                                                                                                      |
| 2.2. Quality aspects                                                                                                       | ..................................................................................................12 |
| 2.2.1. Introduction....................................................................................................12  |                                                                                                      |
| 2.2.2. Active substance                                                                                                    | .............................................................................................13      |
| 2.2.3. Finished medicinal product................................................................................13        |                                                                                                      |
| 2.2.4. Discussion on chemical, and pharmaceutical aspects............................................15                    |                                                                                                      |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ......................16                                                                             |
| 2.2.6. Recommendation(s) for future quality development.............................................16                     |                                                                                                      |
| 2.3. Non-clinical aspects                                                                                                  | ............................................................................................16       |
| 2.3.1. Introduction....................................................................................................16  |                                                                                                      |
| 2.3.2. Ecotoxicity/environmental risk assessment                                                                           | .........................................................16                                          |
| 2.3.3. Discussion on non-clinical aspects......................................................................16          |                                                                                                      |
| 2.3.4. Conclusion on the non-clinical aspects................................................................16            |                                                                                                      |
| 2.4. Clinical aspects                                                                                                      | ..................................................................................................16 |
| 2.4.1. Introduction....................................................................................................16  |                                                                                                      |
| 2.4.2. Pharmacokinetics.............................................................................................18     |                                                                                                      |
| 2.4.3. Pharmacodynamics..........................................................................................23        |                                                                                                      |
| 2.4.4. Post marketing experience................................................................................23         |                                                                                                      |
| 2.4.5. Discussion on clinical aspects                                                                                      | ............................................................................23                       |
| 2.4.6. Conclusions on clinical aspects                                                                                     | ..........................................................................24                         |
| 2.5. Risk management plan........................................................................................24        |                                                                                                      |
| 2.6. PSUR submission................................................................................................25     |                                                                                                      |
| 2.7. Pharmacovigilance..............................................................................................25     |                                                                                                      |
| 2.8. Product information                                                                                                   | ............................................................................................25       |
| 2.8.1. User consultation.............................................................................................25    |                                                                                                      |
| 3. Benefit-risk balance                                                                                                    | ..............................................................................25                     |
| 4. Recommendation...................................................................................26                     |                                                                                                      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

6MWT

6-minute walk test

ADR

Adverse Drug Reaction

AE

Adverse event

AESI

AEs of special interest

ALK1

Activin receptor-like kinase type 1

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

ANSM

National Agency for the Safety of Medicine and Health Products

AP

Applicant's Part of ASMF

API

Active Pharmaceutical Ingredient

APPM

Association of Paediatric Palliative Medicine Master Formulary

AR

Assessment Report

ASM

Active Substance Manufacturer

ASMF

Active Substance Master File = Drug Master File

AST

Aspartate aminotransferase

AUC

Area Under the plasma Concentration

AUC0-inf

Area Under the plasma Concentration-time curve from time zero to infinity

AUC0-t

Area Under the plasma Concentration-time curve from time zero to t hours

BA

BioAvailability

BCT

Blinded combination therapy

BE

Bioequivalence

BID

Bis in die (twice daily)

BMI

Body Mass Index

BMPR2

Bone morphogenetic protein receptor type 2

BNFc

British National Formulary for Children

BNP

Brain natriuretic peptide

BP

Blood pressure

BPH

Benign prostatic hyperplasia

BPI

Brief Pain Inventory

BUN

Blood urea nitrogen

cGMP

Cyclic guanosine monophosphate

CI

Confidence interval

CI

Cardiac index

CIOMS

Suspect Adverse Reaction Report Form

Cl

Clearance

CLcr or CrCl

Creatinine clearance

Cmax

maximum plasma concentration

CMH test

Haenszel test

CO

Cardiac output.

CoA

Certificate of Analysis

CP

Cerebral palsy

CPPs

Critical process parameters

CQAs

Control quality attributes

CRO

Certified Research Organisation

CSF

Cerebrospinal fluid

CTEPH

Chronic thromboembolic pulmonary hypertension

CV

Coefficient of Variation

CW

Clinical worsening

CYP450

cytochrome P450

DAP

Drug Analysis Print

DDI

Drug-drug interactions

DHCP

Direct Healthcare Professional Communication

DMF

Drug Master File = Active Substance Master File

DoE

Design of experiments

DP

Decentralised (Application) Procedure Drug product Drug substance Differential Scanning Calorimetry Europena Commission Electrocardiogram Erectile dysfunction electroencephalogram estimated glomerular filtration rate estimated glomerular filtration rate based on the Chronic Kidney Disease Epidemiology Collaboration equation estimated glomerular filtration rate based on the Modification of Diet in Renal Disease equation echocardiography European Madicines Agency End os Study endothelin receptor antagonist Enviromental Risk Assessment enzyme replacement therapy Electro Spray Ionisation endothelin receptor antagosinsts European Union Final Assessment Visit Forced expiratory volume in one second Failure mode and effects analysis Finish Product Manufacturer Gamma-aminobutyric acid Generalised Anxiety Disorder Good Clinical Practice glomerular filtration rate gamma-glutamyl transpeptidase globotriaosylceramide gene encoding α-Gal A Good Laboratory Practice Good manufacturing practice Glycopyrronium Gastrointestinal Symptoms Rating Scale Guanosine triphosphate Haemoglobin hydrochloride Health Care Professional hematocrit High Density Polyethylene human embryonic kidney High pressure liquid chromatography Hazard Ratio human recommended dose Committee for Human Medicine Products infusion-associated reaction interstitial capillary interstitial capillary GL-3 Informed Consent Document Indian council of medical research Individual Case Safety Report Independent Ethics Committee

DP

DS

DSC

EC

ECG

ED

EEG

eGFR

eGFRCKD-EPI

eGFRMDRD

ECHO

EMA

EoS

ERA

ERA

ERT

ESI

ETA

EU

FAV

FEV1

FMEA

FPM

GABA

GAD

GCP

GFR

GGT

GL-3

GLA

GLP

GMP

GP

GSRS

GTP

Hb

HCl

HCP

HCT

HDPE

HEK

HPLC

HR

HRD

CHMP

IAR

IC

IC GL-3

ICD

ICMR

ICSR

IEC

IgG

immunoglobulin G

<div style=\"page-break-after: always\"></div>

ICH

International Conference on Harmonisation

IIEF

International Index of Erectile Function

IMP

Investigated Medicinal product

IMS

International Marketing Sales

INN

International Non-proprietary Name

IP

investigational product

IPC

In-process control

IR

Incidence Rate

IR

Immediate-release or Infra-red

IRB

Institutional Review Board

IS-normalized MF

Internal Standard-normalised Matrix Factor

ISR

Incurred Sample Reanalysis

ITT

Intention To Treat

IV

Intravenous

JP

Japanese Pharmacopeia

JPE

Japanese Pharmaceutical Excipients

K2EDTA

dipotassium ethylenediaminetetraacetic acid

K i

dissociation constant for binding of inhibitor to enzyme

L

Litres

LC-MS/MS

liquid chromatography coupled with tandem mass spectrometry Liver Function tests

LFT

LLOQ

Lower Limit of Quantification

LOA

Letter of Access

LOD

Limit of Detection

LOQ

(1) Limit of Quantification, (2) List of Questions

LV

left ventricular

LVEDP

Left ventricular end diastolic pressure

LVH

Left ventricular hypertrophy

LVMi

Left ventricular mass index

lyso-Gb3

globotriaosylsphingosine

M.D.

Medical Doctor

MA

Marketing Authorisation

MAA

Marketing Authorization Application

MAH

Marketing Authorisation holder

mBMRS

modified Behavioural and Medical Rating Scale

MC

Multicenter

MDRD

Modification of Diet in Renal Disease equation

MedDRA

Medical Dictionary for Regulatory Activities

mg

milligrams

mGFR

measured glomerular filtration rate

mGFR iohexol

glomerular filtration rate as measured by plasma clearance of iohexol Medicines and Healthcare Products Regulatory Agency

MHRA

mITT

Modified Intended To Treat

mITT-amenable

patients with amenable mutations in the AT1001-011 mITT population milliliters

mL

<div style=\"page-break-after: always\"></div>

mL/min

Milliliter per minute

mPAP

Mean Pulmonary Artery Pressure

MR

Medical Representative

MRI

Magnetic resonance imaging

MS

Mass Spectrometry

mTDS

modified 9-point Teacher's Drooling Scale

MWD

minute walk distance

NAION

Non-Arteritic Anterior Ischemic Optic Neuropathy

NCA

National Competent Authority

ND

Not detected

NHS

National Health Service

NMR

Nuclear Magnetic Resonance

NMT

Not more than

NO

Nitric oxide

NP

Natriuretic peptides

NR

Not reported

NSAID

Non-Steroidal Anti-Inflammatory Drug

NYHA

New York Heart Association

OECD

Organisation for Economic Co-operation and Development

OLE

open-label  extension

OOS

Out of Specifications

OTC

Over-the-counter

PAH

Pulmonary Arterial Hypertension

PASP

Pulmonary artery systolic pressure

PBMC

Peripheral blood mononuclear cell

PBO

Placebo-controlled trial

PCA

Prescription cost analysis data

PCD

Photo-Contact Dermatitis

PCTFE

Polychlorotrifluoroethene

PCWP

Pulmonary capillary wedge pressure

PD

Pharmacodynamics

PDE

Permitted Daily Exposure

PDE-5

Phosphodiesterase type-5 inhibitors

PE

Polyethylene

PEC

Predicted Enviromental Concentration

P-gp

P-glycoprotein

Ph.Eur.

European Pharmacopoeia

PhV

Pharmacovigilance

PCH

Pulmonary capillary hemangiomatosis

PIL

Patient Information Leaflet

PIP

Paediatric Investigational Plan

PK

Pharmacokinetic

PMS

Post Marketing Surveillance

PP

Polypropylene

PRO

Patient-Reported Outcome

<div style=\"page-break-after: always\"></div>

PS

Photo-Sensitivity

PSMF

Pharmacovigilance Systém Master File

PSUR

Periodic Safety Update Report

PT

Preferred Term

PTH

Pituitary thyroid hormone

PUMA

Paediatric Use Marketing Authorisation

PVC

Poly vinyl chloride

PVDC

Polyvinylidene chloride

PVOD

Pulmonary Veno-Occlusive Disease

PVR

Pulmonary vascular resistance

QA

Quality Assurance

QbD

Quality by design

QC

Quality Control (samples)

QD

quaque die (once daily)

QOD

every other day

QOD

quaque otra die (once every other day)

QoL

Quality of life

QOS

Quality Overall Summary

QP

Qualified Person

QTc

QT interval corrected for heart rate

QTPP

Quality target product profile

Rf

Retention factor

RH

Relative Humidity

rhα-Gal A

recombinant human α-Gal A

RMM

Risk Minimization Measure

RMS

Reference Member State

RR

Reporting Rate

RRT

Relative retention time

RSD

Relative standard deviation

Rt

Retention time

RT

Reference/Test (prodcut)

RVSP

Right ventricle systolic pressure

SAE

serious adverse event

SAO2

oxygen saturation

SEM

standard error of the mean

SF-36v2

Short Form Health Survey with 36 questions, version 2

sGC

soluble Guanylate Cyclase

SGLT1

sodium glucose cotransporter 1

SGOT

Serum glutamic oxaloacetic trnasaminase

SGPT

Serum glutamic pyruvic trnasmainase

Shire HGT

Shire human genetic therapies

SME

small, or medium-sized enterprise

SmPC

Summary of Product Characteristics

SMQ

Standardised MedDRA Querie

SOC

System Organ Class

SOP

Standard Operating Procedure

SPC

Summary of Product Characteristics

STD

Standard Deviation

SVR

Systemic vascular resistance

T/R

Test/Reference (product)

t 1/2

terminal elimination half-life

TEAE

treatment-emergent adverse event

TID

tris in die (three times a day)

TLC

Total lung capacity

t max

time to maximum plasma concentration

TSE

Transmissible spongiform encephalopathy

TSQM

Treatment satisfaction questionnaire for medication

TTC

Threshold of toxicological concern

ULN

upper limit of normal

USP

United States pharmacopoeial

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| UV      | Ultraviolet               |
|---------|---------------------------|
| VAS     | visual analogue scale     |
| Vss     | volume of distribution    |
| WBC     | white blood cell          |
| WCI     | Worst Case Imputation     |
| WEU     | Well Established Use      |
| WHO     | World Health Organization |
| WRI     | worst rank imputation     |
| WT      | wild type                 |
| XRD     | X-Ray Diffraction         |
| XRPD    | X-ray powder diffraction  |
| α-Gal A | alpha-galactosidase A     |
| μCi     | Microcurie                |
| μM      | Micromolar                |

Not all abbreviations might be used.

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Mylan S.A.S. submitted on 21 December 2015 an application for marketing authorisation to the European Medicines Agency (EMA) for Tadalafil Generics, through the centralised procedure under Article 3(3) of Regulation (EC) No. 726/2004 - 'Generic of a Centrally authorised product'. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24 September 2015.

The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which a marketing authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC.

The applicant applied for the following indication:

Tadalafil Generics is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.

Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.

## The legal basis for this application refers to:

Generic application (Article 10(1) of Directive No 2001/83/EC).

The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Adcirca instead of non-clinical and clinical studies unless justified otherwise.

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Community provisions in force for not less than 6/10 years in the EEA:

- Product name, strength, pharmaceutical form: Cialis, 20 mg, film-coated tablet
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Date of authorisation: 12/11/2002
- Marketing authorisation granted by:
- -Community
- Community Marketing authorisation number: EU/1/02/237/002-005, 009

Medicinal product authorised in the Community/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Adcirca, 20 mg, film-coated tablet

<div style=\"page-break-after: always\"></div>

- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Date of authorisation: 01/10/2008
- Marketing authorisation granted by:
- -Community
- Community Marketing authorisation number: EU/1/08/476/005-006

Medicinal product which is or has been authorised in accordance with Community provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Adcirca, 20 mg, film-coated tablet
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Date of authorisation: 01/10/2008
- Marketing authorisation granted by:
- -Community
- -Community Marketing authorisation number: EU/1/08/476/006
- Bioavailability study number(s): 080-15, 081-15

## Scientific advice

The applicant did not seek scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur: Radka Montoniová

- The application was received by the EMA on 21 December 2015.
- The procedure started on 28 January 2016.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 15 April 2016. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 28 April 2016.
- During the meeting on 26 May 2016, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 31 May 2016.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 15 July 2016.
- The Rapporteur circulated the Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 18 August 2016.
- During the PRAC meeting on 2 September 2016, the PRAC agreed on a PRAC Assessment Overview and Advice to CHMP. The PRAC assessment Overview and Advice was sent to the applicant on 25 August 2016.
- The CHMP adopted an Assessment Report on similarity for Tadalafil Generics with Volibris, Opsumit and Adempas on 15 September 2016.
- During the CHMP meeting on 15 September 2016, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 11 October 2016.
- During the meeting on 10 November 2016, the CHMP, in the light of the overall data submitted and

<div style=\"page-break-after: always\"></div>

the scientific discussion within the Committee, issued a positive opinion for granting a Marketing authorisation to Tadalafil Generics.

## 2. Scientific discussion

## 2.1. Introduction

The proposed product is an immediate release film-coated 20 mg tablets containing tadalafil as active substance. Tadalafil is a chemical substance and the dosage form has been developed as generic product to the centrally authorised product Adcirca 20 mg Filmtabletten by the company Eli Lilly Nederland B.V., Netherlands containing the same active substance in the same pharmaceutical form.

Tadalafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations within the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of the pulmonary vascular smooth muscle cell and vasodilation of the pulmonary vascular bed.

Tadalafil is approved in the EU for the treatment:

## Adults

Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic pulmonary hypertension and in pulmonary hypertension related to collagen vascular disease.

## About the disease

Pulmonary arterial hypertension (PAH) is a rare disorder with reports estimating its prevalence at between 15 and 52 cases per one million patients (Falk JA et al., 2010). PAH is a chronic disease of the pulmonary vasculature defined as the presence of a mean pulmonary artery pressure &gt;25 mmHg at rest (or &gt;30 mmHg during exercise) in the presence of mean pulmonary capillary wedge pressure &lt;15 mmHg (Katz SD et al., 2008).

The pathogenesis of this disorder is complex and incompletely characterized. Increased pulmonary artery blood pressures are associated with structural changes in the pulmonary circulation characterized by pulmonary arteriopathy (intimal thickening, medial hypertrophy, adventitial thickening, and plexiform lesions), in-situ thrombosis, and rarefaction of the microcirculation (Katz SD et al., 2008).

Clinical manifestations of PAH are related to the hemodynamic effects of increased afterload on the right ventricle and systemic manifestations of the comorbid conditions associated with elevated pulmonary vascular resistance. Progressive exercise intolerance, lower extremity edema, ascites, and syncope are common clinical presentations. Although duplex echocardiography is considered an excellent screening tool in suspected cases, cardiac catheterization with direct measurement of pulmonary artery pressures is required for definitive diagnosis. PAH is associated with progressive right ventricular failure and high mortality risk (Katz SD et al., 2008).

Traditional classification of pulmonary hypertension largely differentiated patients with idiopathic or primary cases from patients with PH from secondary causes. This classification scheme had many limitations as it did not adequately describe underlying mechanisms of the disease and their implications

<div style=\"page-break-after: always\"></div>

for potential treatment options, based on the pathophysiology of the underlying conditions (Falk JA et al., 2010).

## Proposed indication, posology and use in special populations

Tadalafil is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.

Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH.

## Posology

The recommended dose is 40 mg (2 x 20 mg) taken once daily with or without food.

## Special populations

## Elderly patients

Dose adjustments are not required in elderly patients.

## Renal impairment

In patients with mild to moderate renal impairment a starting dose of 20 mg once per day is recommended. The dose may be increased to 40 mg once per day, based on individual efficacy and tolerability. In patients with severe renal impairment the use of tadalafil is not recommended (see sections 4.4 and 5.2).

## Hepatic impairment

Due to limited clinical experience in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A and B), following single doses of 10 mg, a starting dose of 20 mg once per day may be considered. If tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied and therefore dosing of tadalafil is not recommended (see sections 4.4 and 5.2).

## Paediatric population

The safety and efficacy of tadalafil in individuals below 18 years of age has not yet been established. No data are available.

## Method of administration

Tadalafil Generics is for oral use.

## 2.2. Quality aspects

## 2.2.1. Introduction

The proposed product is presented as immediate release film-coated tablets containing 20 mg of tadalafil as active substance. The product has been developed as generic product to the centrally authorised product Adcirca 20 mg film-coated tablets containing the same active substance in the same pharmaceutical form.

Other ingredients are:

<div style=\"page-break-after: always\"></div>

Tablet core: lactose anhydrous, poloxamer 188, cellulose microcrystalline (pH101), povidone (K-25), croscarmellose sodium, magnesium stearate, sodium lauril sulfate, and silica colloidal anhydrous.

Film-coat: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), and triacetin.

The product is available in PVC/PE/PVdC-Alu blisters in carton.

## 2.2.2. Active substance

## General information

The chemical name of tadalafil is (6 R -trans)-6-(1,3-benzodioxol-5-yl)2,3,6,7,12,12 a -hexahydro-2-methyl-pyrazino [1', 2':1,6] pyrido[3,4b ]indole-1,4-dione.

The active substance is a white or almost white powder which is practically insoluble in water, freely soluble in dimethyl sulfoxide and slightly soluble in methylene chloride.

As there is a monograph of tadalafil in the European Pharmacopoeia, the manufacturer of the active substance has been granted a Certificate of Suitability of the European Pharmacopoeia (CEP) for tadalafil which has been provided within the current Marketing Authorisation Application.

## Manufacture, characterisation and process controls

The relevant information has been assessed by the EDQM before issuing the Certificate of Suitability.

## Specification

The control tests were carried out to comply with the specifications and test methods of the Ph. Eur. monograph.

Additional specifications have been set for impurities, residual solvents and particle size. The analytical method for particle size has been adequately validated and it was demonstrated that it is not a critical factor for either the finished product performance or the manufacturing process.

Batch analysis data on three consecutive batches of the active substance were provided. The results comply with the specifications and confirm consistency and uniformity of the manufacturing process.

## Stability

The relevant information has been assessed by the EDQM before issuing the Certificate of Suitability.

## 2.2.3. Finished medicinal product

## Description of the product and pharmaceutical development

The finished product Tadalafil Generics film-coated tablets was developed as a generic bioequivalent to Adcirca by Eli Lilly Nederland B.V. from the European market. The formulation contains the active substance tadalafil, officially listed in the Ph. Eur. Tadalafil is a white or almost white powder, practically insoluble in water, freely soluble in DMSO and slightly soluble in methylene chloride. The excipients selected for the formulation development are based on literature survey, excipient compatibility studies and their functionality for development of a tablet dosage form. The choice and function of the excipients has been adequately described. The excipients in tested product are similar to those found in the originator Adcirca, with the addition of Povidone (binder), Poloxamer (solubilizer), and silica colloidal anhydrous (glidant). All of the excipients are conventional pharmaceutical ingredients that comply with

<div style=\"page-break-after: always\"></div>

the respective requirements of the Ph. Eur., with the exception of the film coating agent Opadry II white. However, the individual components of the coating material comply with Ph.Eur. or EU regulation 231/2012 for the colorants.

The manufacturing process development strategy was to design and develop stable and bioequivalent generic product of Tadalafil film coated tablets using commonly used excipients and similar to reference product. The active substance characterization has revealed that the active substance had very poor flow properties. Therefore a wet granulation process was chosen. During development the manufacturing process was optimized with regard to the following parameters: solvent system for granulation, drying temperature, milling process, blending time, tableting speed and hardness.

The applicant evaluated the dissolution of the reference product in different dissolution media covering different pHs. Different surfactants were also evaluated. Based on the obtained results, the final conditions were selected.

The discriminatory power of the dissolution method has been studied by varying the quantitative composition of the formulation (level of disintegrant) and changing the manufacturing process (lubrication time). The results from this study demonstrated the discriminatory nature of the method proposed.

The dissolution characteristics of the finished product were compared to the reference medicinal product Adcirca from the European market. Comparative dissolution profiles were generated in relevant dissolution media.

In one medium the dissolution profiles were similar. For the other media faster release of drug in the test product was observed when compared to the reference product. This may be due to the difference in the composition between both products. Nevertheless, since Tadalafil is rapidly absorbed after oral administration, the difference in the in-vitro drug release at the initial time points will not have any significant impact on in vivo drug release. This was confirmed by the bioequivalence studies (see clinical section).

The formulation used in the clinical study and the formulation intended for commercial supplies is identical except for the Opadry film coating material which is non-functional in nature.

The primary packaging is PVC/PE/PVdC-Alu blisters. The material complies with Ph. Eur. and EC requirements. The choice of container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product

The product is manufactured using a wet granulation process. The manufacturing process consists of 10 main steps: dispensing, sifting, granulation and drying, milling, mixing of granules, blending, compression, coating, inspection and packaging. The process is considered to be a standard manufacturing process.

Major steps of the manufacturing process have been validated by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this pharmaceutical form.

A process validation scheme has been provided and the applicant has committed to perform process validation studies on the first three production scale batches of Tadalafil 20 mg film coated tablets before the product is placed on the market.

<div style=\"page-break-after: always\"></div>

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form: description, identification (UV, IR), color identification, dissolution (HPLC), uniformity of dosage units (by content uniformity), assay (UV), related substances (HPLC), loss on drying (Ph. Eur.), residual solvents (GC), and microbiological test (Ph. Eur.).

Batch analysis results are provided for three batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

Analytical methods were adequately described. Validations of analytical methods were provided for HPLC methods for assay, related substances and dissolution. Stability indicating capability of the HPLC method for assay, related substances and dissolution has been demonstrated through forced degradation studies.

## Stability of the product

Stability data for five pilot scale  batches of finished product stored under long term conditions at 25ºC / 60% RH for up to 36 months and for 6 months under accelerated conditions at 40ºC / 75% RH according to the ICH guidelines were provided. The batches of the medicinal product were packed in the primary packaging proposed for marketing.

Additional results on the product packed in a simulated bulk shipment pack were provided. This simulated pack only differs in size with the bulk shipment pack which will be use in the commercial setting.

Samples were tested for description, dissolution, assay (HPLC), related substances, loss on drying and microbiological quality. The analytical procedures used are stability indicating.

No change to the appearance of the tablets was observed under any of the conditions tested. Dissolution, assay, related substances, loss on drying and microbiological (if tested) results were within the shelf life specification limits at all time points in all the proposed packs. In addition, 1 batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. No significant difference in any of the parameters tested (namely, description, assay, related substances, loss on drying and dissolution) was observed. Therefore, it was concluded that Tadalafil Generics 20 mg film-coated tablets are photostable.

Based on the accelerated (24 weeks at 40ºC / 75% RH) and long-term (12 months at 25ºC / 60% RH) stability results on the product packaged in to simulated bulk shipment pack, a 12 month shelf life with no special storage conditions can be accepted for this packaging.

Based on available stability data, the proposed shelf-life of 3 years with no special storage conditions as stated in the SmPC is acceptable.

## Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.2.4. Discussion on chemical and pharmaceutical aspects

Information on development, manufacture and control of the active substance and the finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and

<div style=\"page-break-after: always\"></div>

uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation(s) for future quality development

Not applicable

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The impurity profile has been discussed and was considered acceptable.

Therefore, the CHMP agreed that no further non-clinical studies are required.

## 2.3.2. Ecotoxicity/environmental risk assessment

No Environmental Risk Assessment was submitted. This was justified by the applicant as the introduction of Tadalafil Generics manufactured by Mylan S.A.S. is considered unlikely to result in any significant increase in the combined sales volumes for all tadalafil containing products and the exposure of the environment to the active substance. Thus, the ERA is expected to be similar and not increased.

## 2.3.3. Discussion on non-clinical aspects

The non-clinical overview on the pre-clinical pharmacology, pharmacokinetics and toxicology was considered adequate by the CHMP.

A valid justification for not submitting an ERA was provided.

## 2.3.4. Conclusion on the non-clinical aspects

A summary of the literature with regard to non-clinical data of Tadalafil Generics was provided and was accepted by the CHMP. This was in accordance with the relevant guideline and additional non clinical studies were not considered necessary.

## 2.4. Clinical aspects

## 2.4.1. Introduction

This is an application for tablets containing tadalafil. To support the marketing authorisation application the applicant conducted two bioequivalence studies with cross-over design under fasting and fed

<div style=\"page-break-after: always\"></div>

conditions. These studies were the pivotal studies for the assessment.

No CHMP scientific advice pertinent to the clinical development was given for this medicinal product.

For the clinical assessment the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98) as well as the Guideline on Bioanalytical method validation (EMEA/CHMP/EWP/192217/09) and Question number 10 of the Questions &amp; Answers: Positions on specific questions addressed to the Pharmacokinetics Working Party (EMEA/618604/2008 rev.13) are of particular relevance.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## Clinical studies

To support the application, the applicant has submitted two bioequivalence studies.

According to the EMA Tadalafil product-specific guidance (CHMP/PKWP/EMA/423735/2013), the reference product is considered to have specific formulation characteristics to enhance the rate of absorption of the drug and therefore, it cannot be assumed that the impact of food will be the same regardless of formulation. The product can be taken without regard to food. Thus, both fasted and fed state comparisons of test to reference formulations are required to establish bioequivalence.

Table 1. Tabular overview of clinical studies

| Type of study   | Study Identifier   | Objective of the study                                                                                                                                                                                                                            | Study design and type of control                                                                                                                                                                      | Test Products; Dosage regimen; Route of administration                                                                                                   | Number of subjects                                                                                                                                                                    | Healthy subjects or diagnosis of patients   | Duration of treatment   |
|-----------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|-------------------------|
| BE              | 080-15             | Primary objective To compare the rate and extent of absorption of Tadalafil Film-coated Tablets 20 mg (Test) of Mylan Laboratories Limited, with that of Adcirca (Tadalafil) 20 mg Tablets (Reference) Secondary objective To monitor the adverse | An open-label, balanced, randomized, two-treatment, two sequence, two-period, cross-over, single dose, oral bio- equivalence study, in healthy, adult, male, human subjects under fasting conditions. | Test product Tadalafil Film-coated Tablets 20 mg Reference Product Adcirca (Tadalafil) 20 mg Tablets Single dose of 20 mg tablet for oral administration | Planned - 30 subjects Enrolled - 30 subjects Dosed : Period-1 : 30 Subjects Period-2 : 26 Subjects Withdrawn - 04 subjects Completed - 26 Subjects Pharmaco- kinetic statistical data | Healthy, adult, human subjects              | Single dose             |

<div style=\"page-break-after: always\"></div>

|    |        | events and to ensure the safety of the subjects.                                                                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                                                                                                          | analyzed - 26 Subjects                                                                                                                                                       |                                |             |
|----|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------|
| BE | 081-15 | Primary objective To compare the rate and extent of absorption of Tadalafil Film-coated Tablets 20 mg (Test) of Mylan Laboratories Limited, with that of Adcirca (Tadalafil) 20 mg Tablets (Reference) Secondary objective To monitor the adverse events and to ensure the safety of the subjects. | An open-label, balanced, randomized, two-treatment, two sequence, two-period, cross-over, single dose, oral bio- equivalence study, in healthy, adult, male, human subjects under fed conditions. | Test product Tadalafil Film-coated Tablets 20 mg Reference Product Adcirca (Tadalafil) 20 mg Tablets Single dose of 20 mg tablet for oral administration | Planned - 30 Enrolled - 30 Withdrawn - 03 subjects Completed - 27 Subjects Bio-sample analyzed - 27 Subjects. Pharmaco- kinetic and statistical data analyzed - 27 Subjects. | Healthy, adult, human subjects | Single dose |

## 2.4.2. Pharmacokinetics

## Study No. 080-15

## Methods

## Study design

This study was an open-label, balanced, randomised, two-treatment, two-sequence, two period, cross-over, single dose, oral bioequivalence study of two different tadalafil formulations in adult, male, human subjects under fasting conditions. A washout period of 14 days was maintained between the each treatment schedule.

## Test and reference products

Tadalafil Generics 20 mg film-coated tablets manufactured by Mylan Laboratories Ltd, India (batch No 2001691, manufacturing date 12/2012; exp. Date 11/2014) has been compared to Adcirca 20mg film-coated tablets manufactured by Eli Lilly Nederland BV, Netherlands (Batch No: C458281, exp. Date 11/2017).

## Population studied

Thirty (30) male, healthy subjects of Asian race, with a mean body mass index 22.83 kg/m 2  (range 18.81 - 26.34), and mean age 28 years (range: 21-39) were included in the study.

<div style=\"page-break-after: always\"></div>

Four (4) patients in total withdrew from the study.  One patient was absent during the check-in of the second period of the study. The other 3 patients withdrew due to an adverse event.

## Analytical methods

Tadalafil concentrations were determined by HPLC method by tandem mass spectrometry and using tadalafil-d3 as an internal standard.

Calibration curves ranged from 2.011 to 603.915 ng/mL. Quantitation was based on peak area ratio of tadalafil versus internal standard. A least squares linear regression with weighing factor 1/x 2 was used.

Samples were analysed in nineteen (19) accepted analytical runs including repeats and ISR each of them containing blank and zero samples in singlet, ten calibration standards and QC samples at five levels distributed throughout the batch of samples from both periods of two subjects.

Blank samples were chromatographically checked and no peaks were found at the retention time of analyte and ISTD. This demonstrated that there was no interference due to endogenous matrix constituents. Blank samples were run after the highest calibration curve standard.

Incurred Sample Reanalysis (ISR) was performed by using freshly prepared calibration standards and 79.63% of ISR samples were found to be within acceptance limits.

There were no protocol or SOP deviation occurred during the study.

Tadalafil was detected in several pre-dose samples in the quantities lower than 1/20 of Cmax in accordance with the Guideline on investigation of bioequivalence CPMP/EWP/QWP/1401/98 Rev.1.

## Den

The PK parameters for tadalafil were calculated by using non-compartmental model by WinNonlin Professional Software (version 5.0).

## Statistical methods

Descriptive statistics were computed and reported for all pharmacokinetic parameters of tadalafil. Analysis of variance (ANOVA) was carried out for Ln-transformed pharmacokinetic parameters Cmax and AUC0-72hr for tadalafil. ANOVA model included treatment received, the period at which it is given along with the sequence in which each treatment being received and the subject effect (nested within the sequence). Sequence effect was tested by using the subject nested within sequence mean square from the ANOVA as the error term. An F-test was performed to determine the statistical significance of the treatment and periods involved in the model at a significance level of 5% (alpha=0.05) and sequence effect involved in the model at a significance level of 10% (alpha=0.10). Summary statistics, ANOVA, 90% confidence intervals, ratio analysis, intra subject variability and power were calculated for tadalafil. Geometric means and ratio of means were calculated for tadalafil.

90% confidence intervals for the ratio of the test and reference product averages (geometric least squares means) were calculated for Cmax and AUC0-72hr of tadalafil.

Criteria for conclusion of bioequivalence were as follows:

| Parameter   | Range of Ln-transformed 90% CI of Tadalafil   |
|-------------|-----------------------------------------------|
| C max       | 83.88-97.22                                   |
| AUC 0-72hr  | 92.91-103.25                                  |

The 90% confidence intervals for geometric least square means of ln-transformed data of Cmax and AUC0-72hr of tadalafil were within the bioequivalence acceptance range (80.00 -125.00%).

<div style=\"page-break-after: always\"></div>

## Results

Table 2. Pharmacokinetic parameters for tadalafil under fasting condition (non-transformed values)

| Pharmacokinetic parameter                                                                                                                                             | Test                                                                                                                                                                  | Test                                                                                                                                                                  | Reference                                                                                                                                                             | Reference                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pharmacokinetic parameter                                                                                                                                             | arithmetic mean                                                                                                                                                       | SD                                                                                                                                                                    | arithmetic mean                                                                                                                                                       | SD                                                                                                                                                                    |
| AUC (0-72h) (hr.ng/mL)                                                                                                                                                | 18651.86                                                                                                                                                              | 5280.82                                                                                                                                                               | 18886.53                                                                                                                                                              | 4686.28                                                                                                                                                               |
| AUC (0-∞) (hr.ng/mL)                                                                                                                                                  | 26852.14                                                                                                                                                              | 12220.99                                                                                                                                                              | 26710.86                                                                                                                                                              | 9980.00                                                                                                                                                               |
| C max (ng/ml)                                                                                                                                                         | 530.26                                                                                                                                                                | 141.07                                                                                                                                                                | 582.61                                                                                                                                                                | 134.34                                                                                                                                                                |
| T max * (hr)                                                                                                                                                          | 3.75 (0.50 - 24.00)                                                                                                                                                   |                                                                                                                                                                       | 3.00 (0.50 - 4.50)                                                                                                                                                    |                                                                                                                                                                       |
| AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0-72h area under the plasma concentration-time curve from time zero to 72 hours> | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0-72h area under the plasma concentration-time curve from time zero to 72 hours> | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0-72h area under the plasma concentration-time curve from time zero to 72 hours> | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0-72h area under the plasma concentration-time curve from time zero to 72 hours> | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0-72h area under the plasma concentration-time curve from time zero to 72 hours> |

Table 3. Statistical analysis for tadalafil under fasting conditions (ln-transformed values)

| Pharmacokinet ic parameter   | Geometric Mean Ratio Test/Reference   | 90% Confidence Interval   |   CV%* |
|------------------------------|---------------------------------------|---------------------------|--------|
| AUC (0-72h)                  | 97.95%                                | (92.91%, 103.25%)         |   11.2 |
| C max                        | 90.31%                                | (83.88%, 97.22%)          |   15.6 |

There were four pre-dose concentrations in period II, however these subjects were included for bioanalysis, pharmacokinetic analysis and statistical evaluations as these subjects showed pre-dose values lower than 5% of Cmax.

## Safety data

In total six adverse events were reported in five subjects during entire duration of the study.

- Three  adverse events were reported in three subjects during period-I (vomiting, pyrexia, diarrhoea)
- One adverse event was reported in one subject during period-II check-in (pyrexia)
- No adverse events were reported in Period-II.
- Two adverse events were reported in two subjects as laboratory abnormalities during post study lab investigations.

No deaths or serious adverse events were reported during the study.

<div style=\"page-break-after: always\"></div>

## Study No. 081-15

## Methods

## Study design

This study was an open-label, balanced, randomised, two-treatment, two-sequence, two period, cross-over, single dose, oral bioequivalence study of two different tadalafil formulations in adult, male, human subjects under fed conditions. A washout period of 14 days was maintained between the each treatment schedule.

## Test and reference products

Tadalafil Generics 20 mg film-coated tablets manufactured by Mylan Laboratories Ltd, India (batch No 2001691, manufacturing date 12/2012; exp. Date 11/2014) has been compared to Adcirca 20mg film-coated tablets manufactured by Eli Lilly Nederland BV, Netherlands (Batch No: C458281, exp. Date 11/2017).

## Population studied

Thirty (30) male, healthy subjects of Asian race, with a mean body mass index 23.24 kg/m 2  (range 18.80 - 28.35), and mean age 27.63 years (range: 20-43) were included in the study.

Three (3) patients withdrew from the study, as they were absent for the check-in of the second period of the study.

## Analytical methods

Tadalafil concentrations were determined by HPLC method by tandem mass spectrometry and using tadalafil-d3 as an internal standard.

Calibration curves ranged from 2.012 to 603.587 ng/m. Quantitation was based on peak area ratio of tadalafil versus internal standard. A least squares linear regression with weighing factor 1/x 2 was used.

Samples were analysed in nineteen (19) accepted analytical runs including repeats and ISR each of them containing blank and zero samples in singlet, ten calibration standards and QC samples at five levels distributed throughout the batch of samples from both periods of two subjects.

Blank samples were chromatographically checked and no peaks were found at the retention time of analyte and ISTD. This demonstrated that there was no interference due to endogenous matrix constituents. Blank samples were run after the highest calibration curve standard.

Incurred Sample Reanalysis (ISR) was performed by using freshly prepared calibration standards and 95.37% of ISR samples were found to be within acceptance limits.

There were no protocol or SOP deviation occurred during the study.

Tadalafil was detected in nineteen (19) of fifty four (54) pre-dose samples. There is not any subject for whom the pre-dose concentration is greater than 5 percent of the Cmax value for the subject in that period. Therefore no subject was excluded from statistical analysis.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic variables

These were the same as for Study No. 081-15.

## Statistical methods

These were the same as for Study No. 081-15.

Criteria for conclusion of bioequivalence were as follows:

| Parameter   | Range of Ln-transformed 90% CI of Tadalafil   |
|-------------|-----------------------------------------------|
| C max       | 103.24-119.22                                 |
| AUC 0-72hr  | 95.31-109.80                                  |

The 90% confidence intervals for geometric least square means of ln-transformed data of Cmax and AUC0-72hr of tadalafil were within the bioequivalence acceptance range (80.00 -125.00%).

## Results

Table 4. Pharmacokinetic parameters for tadalafil under fed conditions, (non-transformed values)

| Pharmacokinetic               | Pharmacokinetic                                                                                                                                     | Test                       | Test                           | Reference          | Reference                                                                                                                                           |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| parameter                     | parameter                                                                                                                                           | arithmetic mean            | SD                             | arithmetic mean    | SD                                                                                                                                                  |
| AUC (0-72h) (hr.ng/mL)        | AUC (0-72h) (hr.ng/mL)                                                                                                                              | 14376.53                   | 3983.43                        | 14055.04           | 3122.90                                                                                                                                             |
| AUC (0-∞)                     | AUC (0-∞)                                                                                                                                           | 21192.58                   | 12469.98                       | 20763.95           | 9784.04                                                                                                                                             |
| C max (ng/ml)                 | C max (ng/ml)                                                                                                                                       | 501.12                     | 135.20                         | 446.58             | 64.70                                                                                                                                               |
| T max * (hr)                  | T max * (hr)                                                                                                                                        | 4.00 (1.00 - 4.50)         |                                | 4.50 (1.00 - 8.00) |                                                                                                                                                     |
| AUC 0-72h AUC 0-∞ C max T max | area under the plasma concentration-time curve from time zero to 72 hours area under the plasma concentration-time curve from time zero to infinity | maximum plasma for maximum | concentration concentration (* | median, range)     | area under the plasma concentration-time curve from time zero to 72 hours area under the plasma concentration-time curve from time zero to infinity |

Table 5. Statistical analysis for tadalafil under fed conditions (ln-transformed values)

| Pharmacokinetic parameter   | Geometric Mean Ratio Test/Reference   | 90 %Confidence Interval   |   CV%* |
|-----------------------------|---------------------------------------|---------------------------|--------|
| AUC (0-72h) (hr.ng/mL)      | 102.30%                               | (95.31%, 109.80%)         |   15.3 |

<div style=\"page-break-after: always\"></div>

| Pharmacokinetic parameter   | Geometric Mean Ratio Test/Reference   | 90 %Confidence Interval   |   CV%* |
|-----------------------------|---------------------------------------|---------------------------|--------|
| C max (ng/ml)               | 110.94%                               | (103.24%, 119.22%)        |   15.6 |

In fourteen (14) pre-dose samples from Period-2 tadalafil was detected in concentrations 1.4 - 34 times lower than LLOQ. However pre-dose samples of six (6) subjects from Period-2 contained tadalafil in concentrations 1.1 - 8.1 times higher than LLOQ.

## Safety data

In total thirteen adverse events were reported in five subjects during entire duration of the study.

- Three adverse events were reported in three subjects during period-I (headache and myalgia in two subjects)
- Ten adverse events were reported in six subjects as laboratory abnormalities during post study lab investigations.
- No adverse events were reported in Period-II.

There were no serious adverse events or deaths reported in the study.

## Conclusions

Based on the presented bioequivalence studies, Tadalafil Generics 20 mg film-coated tablets are considered bioequivalent with Adcirca20 mg film-coated tablets.

## 2.4.3. Pharmacodynamics

No new pharmacodynamic studies were presented and no such studies are required for this application.

## 2.4.4. Post marketing experience

The medicinal product has not been marketed in any country in the EU.

## 2.4.5. Discussion on clinical aspects

To support the application, the Applicant conducted two open-label, balanced, randomised, two-treatment, two-sequence, two period, cross-over, single dose, oral bioequivalence studies of Tadalafil Film-coated Tablets 20 mg (Test) of Mylan Laboratories Limited and Adcirca (Tadalafil) 20 mg Tablets (Reference) of Eli Lilly Nederland B.V. in healthy, adult, male, human subjects under fasting and fed conditions.

In both studies, the ratio of the geometric least squares mean of test product and reference product for the      the AUC 0-∞ and for the Cmax was within the pre-specified bioequivalence limits of 80.00-125.00%.

<div style=\"page-break-after: always\"></div>

## 2.4.6. Conclusions on clinical aspects

A summary of the literature with regard to clinical data of tadalafil and two bioequivalence studies were provided to demonstrate that the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product and was accepted by the CHMP.

## 2.5. Risk management plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                 |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Priapism (MedDRA PT: Priapism) • Hypotension/Increased Hypotensive Effect (MedDRA PTs: Hypotension, Blood pressure decreased)                                                                                                                                                                            |
| Important potential risks    | • Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (MedDRA PT: Optic ischaemic neuropathy) • Sudden Hearing Loss (MedDRA HLT: Hearing losses) • Increased uterine bleeding (MedDRA PTs: menorrhagia, polymenorrhagia, metrorrhagia, menometrorrhagia, uterine haemorrhage and vaginal haemorrhage) |
| Missing information          | None                                                                                                                                                                                                                                                                                                       |

## Pharmacovigilance plan

Not applicable.

## Risk minimisation measures

| Safety concern                                                                      | Routine risk minimisation measures                                                                                                                            | Additional risk minimisation measures   |
|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Important identified risks: Priapism                                                | Sections 4.4 and 4.8 of the SPC contain adequate information on this safety concern. Sections 2 and 4 of PL advise patients on this safety concern.           | None                                    |
| Important identified risks: Hypotension/Increased Hypotensive Effect                | Sections 4.3, 4.4, 4.5 and 4.8 of the SPC contain adequate information on this safety concern. Sections 2 and 4 of PL advise patients on this safety concern. | None                                    |
| Important potential risks: Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | Sections 4.3, 4.4, 4.5 and 4.8 of the SPC contain adequate information on this safety concern. Sections 2 and 4 of PL advise patients on this safety concern. | None                                    |
| Important potential risks: Sudden Hearing Loss                                      | Sections 4.3, 4.4 and 4.8 of the SPC contain adequate information on this safety concern. Sections 2 and 4 of PL advise patients on this safety concern.      | None                                    |
| Important potential risks: Increased uterine bleeding                               | Section 4.8 of the SPC contains adequate information on this safety concern. Sections 4 of PL advise patients on this safety concern.                         | None                                    |

<div style=\"page-break-after: always\"></div>

## Conclusion

The CHMP and PRAC considered that the risk management plan version 1.0 is acceptable.

## 2.6. PSUR submission

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8. Product information

## 2.8.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to the design and layout of Duloxetine Mylan 30 mg Hard gastro-resistant capsules (EMEA/H/C/003981). Furthermore, the content of the Tadalafil Generics 20- mg film-coated tablets was prepared to be identical with the leaflet the reference product, ADCIRCA 20 mg film-coated tablets  The bridging report submitted by the applicant has been found acceptable.

## 3. Benefit-risk balance

This application concerns a generic version of tadalafil tablets. The reference product Adcirca 20 mg tablets is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. No non-clinical studies have been provided for this application but an adequate summary of the available nonclinical information for the active substance was presented and considered sufficient. From a clinical perspective, this application does not contain new data on the pharmacokinetics and pharmacodynamics or the efficacy and safety of the active substance; the applicant's clinical overview on these clinical aspects based on information from published literature was considered sufficient.

The applicant submitted two open-label, balanced, randomised, two-treatment, two-sequence, two period, cross-over, single dose, oral bioequivalence studies of two different tadalafil formulations in adult, male, human subjects. One study was performed under fed conditions and the other under fasting conditions. The design of the studies was considered adequate to evaluate the bioequivalence of this formulation and line with the respective European requirements. Choice of dose, sampling points, overall sampling time as well as wash-out periods were adequate. The analytical method was validated. Pharmacokinetic and statistical methods applied were adequate.

The test formulation of Tadalafil Generics 20 mg film-coated tablets met the protocol-defined criteria for bioequivalence when compared with the Adcirca 20mg film-coated tablets. The point estimates and their 90% confidence intervals for the parameters AUC0-∞ , and Cmax were all contained within the protocol-defined acceptance range of [range, e.g. 80.00 to 125.00%]. Bioequivalence of the two formulations was demonstrated.

<div style=\"page-break-after: always\"></div>

A benefit/risk ratio comparable to the reference product can therefore be concluded.

## 4. Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Tadalafil Generics is favourable in the following indication: treatment in adults of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).

Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.